Ivabradine is recommended as an option for treating chronic heart failure for people:1

  • with New York Heart Association (NYHA) class II to IV stable chronic heart failure
  • with systolic dysfunction and
  • who are in sinus rhythm with a heart rate of 75 beats per minute (bpm) or more and
  • who are given ivabradine in combination with standard therapy including betablocker therapy, angiotensin-converting enzyme (ACE) inhibitors and aldosterone antagonists, or when beta-blocker therapy is contraindicated or not tolerated and
  • with a left ventricular ejection fraction of 35% or less.

NICE technology appraisal guidance 267 – Ivabradine for treating chronic heart failure. November 2012.